The Dechorinated Zebrafish Embryo Developmental toxicity assay was originally developed from a training set of 31 compounds and reported to be 87% concordant with in vivo teratogenicity data (Brannen, K. C., Panzica-Kelly, J. M., Danberry, T. L., and Augustine-Rauch, K. A. (2010). Development of a zebrafish embryo teratogenicity assay and quantitative prediction model. Birth Defects Res. 89, 66-77.). The assay includes scoring larva treated in a concentration range for malformations of specific morphological structures/organ systems. The model includes identifying a no-adverse-effectlevel (NOAEL) and the concentration resulting in 25% lethality (LC 25 ) at 5 days postfertilization. An LC 25 /NOAEL ratio !10 classifies a compound positive for teratogenic potential. A consortium effort evaluated a modified version of this assay which involved enzymatic chorion treatment instead of manual dissection and used experimental replicates for final classification. The modified assay achieved an 85% overall predictivity (Gustafson, A. L., Stedman, D. B., Ball, J., Hillegass, J. M., Flood, A., Zhang, C. X., Panzica-Kelly, J., Cao, J., Coburn, A., Enright, B. P., et al. (2012) . Inter-laboratory assessment of a harmonized zebrafish developmental toxicology assay -progress report on phase I. Reprod. Toxicol. 33,[155][156][157][158][159][160][161][162][163][164]. The objective of this study was to perform a thorough performance evaluation of the dechorinated assay by repeating the original training set and testing additional compounds in experimental replicates. When the initial training set was repeated with inclusion of experimental replicates, the overall predictivity was 83%. Model performance was tested with an additional 34 compounds and achieved overall predictivity of 74%. When the training and test sets were combined (63 compounds) the assay's final sensitivity was 83% and the specificity was 71%. Total predictivity was 78% with relatively balanced predictivity for nonteratogens (77%) and teratogens (78%). The chorion-off assay achieved superior sensitivity (83%) compared with sensitivity (63-74%) reported by consortium efforts testing a similar assay with chorion-intact embryos (Ball, J. S., Stedman, D. B., Hillegass, J. M., Zhang, C. X., Panzica-Kelly, J., Coburn, A., Enright, B. P., Tornesi, B., Amouzadeh, H. R., Hetheridge, M., et al. (2014) . Fishing for teratogens: a consortium effort for a harmonized zebrafish developmental toxicology assay. Toxicol. Sci. 139, 210-219.). Additional protocol modifications were made to increase assay throughput.
An increased need to reduce animal use for embryotoxicity testing of chemicals has lead to the development of multiple in vitro teratogenicity screens (Brown and Fabro, 1981; Flint, 1993; Panzica-Kelly et al., 2013; Seiler et al., 2004; Walmod et al., 2002; Zhang et al., 2012) . In order for these screens to be useful they should be repeatable, inexpensive, medium to high throughput and have good concordance with in vivo teratogenicity data of a large (!50) compound set. Availability of multiple in vitro assays that represent different species and developmental stages is also essential. Therefore zebrafish embryos are an attractive model for developmental toxicity screening. Their rapid rate of development and their transparency allow for compound exposure and visualization throughout gastrulation and organogenesis. Also, zebrafish are inexpensive, easy to breed and produce hundreds of embryos daily.
Several laboratories have demonstrated good concordance when utilizing diverse zebrafish models for developmental toxicity testing (Busquet et al., 2008; Lantz-McPeak et al., 2015; McAleer et al., 2005; McGrath and Li, 2008; Nagel, 2002; Parng et al., 2002; Selderslaghs et al., 2009; Weigt et al., 2011) . In particular, a chorion-off zebrafish embryo screen developed by the Tanguay Laboratory at the Oregon State University that utilizes mortality, behavioral and >15 morphological endpoints to assess developmental toxicity has been used to test >300 U.S. EPA ToxCast chemicals with good concordance with in vivo data (Padilla et al., 2012; Truong et al., 2014) . Furthermore, Noyes et al., (2015) has successfully applied this assay to predict developmental toxicity of flame retardants with 93% concordance. Brannen et al. (2010) developed a chorion-off zebrafish teratogenicity assay where compound-induced structure/organ system dysmorphology in 5-day postfertilization larvae was used to identify a no-observed-adverse-effect level (NOAEL). The LC 25 (the concentration resulting in 25% lethality) was calculated, and an LC 25 /NOAEL ratio (Teratogenic Index, TI) was calculated to classify for in vivo teratogenic potential. If the TI ! 10, then the compound is classified as positive for teratogenic potential. This model was developed with 31 definitive animal teratogens and nonteratogens and it was calculated to be 87% concordant. Although promising, the model was not performance-tested with a new test set as a form of cross-validation. Furthermore, this model requires some labor intensive procedures including morphological scoring of all concentration groups to identify a NOAEL, and enzymatic treatment with manual removal of the chorion. The latter raised the question as to whether chorion removal was necessary to maintain good assay sensitivity. A few studies demonstrated increased sensitivity with chorion-on versus chorion-off embryos (Henn and Braunbeck, 2011; Kim and Tanguay, 2014) , and even an automated chorion removal system has been developed (Mandrell et al., 2012) with the assumption that the presence of the chorion affects sensitivity to toxicological effects. Furthermore, a consortium effort using a distinct test set of 20 compounds and wild type strains further evaluated a modified form of our assay which included enzymatic treatment to permeabilize the chorion in lieu of manual dissection and used experimental replicates for final teratogenic classification. With this approach, 88% overall predictivity was achieved (Gustafson et al., 2012) .
Given the promising results of the original chorion-off study and the consortium Phase I assessment with enzymatictreatment of chorions, this study focused on an extended performance assessment of this assay that included experimental replicates and a comprehensive test set including compounds from the original Brannen et al. training set, and consortium Phase I compounds as well as additional compound data. The overall protocol was reviewed for methods to improve throughput including whether enzymatic treatment was sufficient for maintaining optimal performance and methods to reduce the scope of morphological assessment required for teratogenic classification.
The original compounds from the chorion-off assay were retested in replicates and used as the training set and then crosstested with an additional 34 compounds as a form of rigorous performance evaluation. A direct comparison of chorion-on data generated by a zebrafish consortium (Ball et al., 2014; Gustafson et al., 2012) and chorion-off data generated in this study was made to determine whether the chorion made a difference in the sensitivity and specificity of the assay. Finally as a means to determine approaches to simplify score assessment, we compared whether scoring the concentration groups above and below the LC 25 would provide the same teratogenic classification. This method would reduce the number of larva requiring scoring and increase throughput.
MATERIALS AND METHODS
Test chemicals. The training compound set is the list of positive and negative teratogens that was used to build the teratogenicity classification model. The training set was composed of 29 compounds (12 nonteratogens and 17 teratogens) classified based on in vivo data as previously described (Brannen et al., 2010, Supplementary Table 1 ). Preliminary studies suggested that compounds known to have H1 histamine and GABA activity performed poorly in this assay (although the assay was able to detect morphological effects with most of the teratogens tested, it misclassified 50% of the nonteratogen with a 43% total predictivity error rate), therefore these compounds (clozapine, phenobarbital and valproic acid) were excluded from the repeat studies of the original training set. BMS-14 was no longer available for testing in the repeat studies. The test compound set is a distinct list of positive and negative teratogens from the training set that was used to test the performance of the teratogenicity classification model. The test set was comprised of 34 compounds (16 nonteratogens and 18 teratogens) of known in vivo teratogenicity (Supplementary Table 2 ). An attempt to mainly select pharmaceutical compounds for the training and test set was made since this screen was designed to test teratogenicity potential of pharmaceutical compounds. Training and test set compounds were defined as teratogens or nonteratogens based on propriety and/or published in vivo data summarized in the Catalog of Teratogenic Agents (Shepard, 2007) . Compounds were grouped as positive if they induced malformations at doses that were less than or equal to doses that caused minimal to no maternal toxicity in at least one species. Compounds were grouped as negative if despite the presence of maternal toxicity there were no observations of morphological malformations in at least 2 species. The ratio between teratogens and nonteratogens is not equal in the training set because a number of compounds were removed due to having histaminergic and/or GABAnergic pharmacology, which was sub sequentially identified as having higher false positive error rates than other pharmacological classes in the zebrafish assay (Augustine-Rauch et al., submitted).
Animal care and egg production. Healthy mature zebrafish pairs were used for egg production. Wild-type AB line (Zebrafish International Resource Center, Eugene, OR) was used in the initial study and bred and maintained as previously described . The AB strain exhibited high morphological and viability background rates, as well as low fecundity. Furthermore, a recent study suggests variability observed in compound classification using this assay was unrelated to strain differences (Ball et al., 2014) . Therefore, a wild-type pondderived strain (Segrest Farms, Gibsonton, FL) was used for all subsequent studies (all training set repeat studies and testing set) and bred and maintained as previously described (Gustafson et al., 2012) . Briefly, tank water was maintained at 28 (61) C, pH 7.35 (60.65) and the room on a 14-h light: 10-h dark light cycle. Adult fish were co-habited in a 2:1 female to male ratio and egg traps were added to the tanks the night prior to egg collection. Soon after spawning, eggs were collected and incubated at 28 C in embryo medium for approximately 1-2 h.
Assay chemicals. Dimethyl sulfoxide (DMSO; Sigma-Aldrich, St Louis, MO) or phosphate buffered saline (PBS; Invitrogen, Carlsbad, CA) were used as compound vehicles. Pronase E (protease from streptomyces griseus, Sigma-Aldrich, St Louis MO, catalogue No. P6911) was used to weaken the chorions after the 1-2-h initial incubation; the eggs were exposed to 30-60 s of 2 mg/ml pronase solution followed by several washes in embryo medium and a 2-3-h incubation at 28 C. Final concentration of a 0.18 mg/ml tricaine methanesulfonate (Argent Chemical Laboratories, Redmond, WA) solution prepared in ultrapure deionized water adjusted to pH of 7.2 was used to anesthetize the larvae on the day of morphological assessment.
Culture medium and reagents. For the initial AB strain study, embryo medium prepared with Hanks' solutions was used and was prepared as previously described Westerfield, 2000) . For the repeat of the training set and the test set experiments, Danieau's solution was used and prepared as previously described (Gustafson et al., 2012 ). Danieau's solution was used instead of Hank's solutions due to easier and faster formulation on experimental days.
Compound administration. The initial study (completed with AB fish strain) and the first repeat of most of the test set (completed with wild-type Segrest pond fish) chorions were manually dechorionated with fine forceps after the 2-3-h incubation. As a means to compare whether the chorions made a difference in the final teratogenicity classification of a subset of compounds, treated chorions were left intact after the incubation. Individual embryos (4-6-h postfertilization) with or without chorions were transferred to 6-12 wells of 24-well plates containing compound-treated medium as previously described Gustafson et al., 2012) . The solvent (DMSO or PBS) concentration was 0.5 %. This concentration of solvent facilitates solubility of pharmaceutical compounds, and has not exhibited an increase in mortality or malformations compared with untreated controls. Generally, 4 compound concentrations were assessed (0.1, 1, 10, and 100 uM); however, these concentrations were modified in the repeat studies as a means to adapt to compound solubility limitations and to identify LC 25 and NOAEL values if the initial concentration range was not optimal. All embryos were incubated for 5 days at 28 C.
Viability assessment and morphological scoring. On day 5 postfertilization, viability assessment and morphological scoring was performed as previously described Gustafson et al., 2012; Panzica-Kelly et al., 2010) . Briefly, all larvae were assessed for viability by heartbeat evaluation and a 25% lethality concentration (LC 25 ) was extrapolated using curve-fitting. Larvae were morphologically evaluated using a numerical score system designed to assess malformations in several structures. The structures/organs morphologically assessed were: somites, notochord, tail, fins, heart, facial structures, neural tube, and pharyngeal arches/jaws. A score of 5-0.5 was assigned to each endpoint delineating the severity of the defects from normal larvae as previously described Panzica-Kelly et al., 2010) . A score of 5 was assigned to structures with normal morphology, a score of 4 was assigned to structures with variations within normal range. A score of 3 was assigned to structures with mild malformations, a score of 2 was assigned to endpoints with moderate malformations, and a score of 1 was assigned to structures with severe malformations. A score of 0.5 was assigned when structures/organs were not present. The stomach, yolk ball, liver, pigmentation, swim bladder, and body shape were also assessed descriptively. The Lowest Adverse Effect Level (LOAEL) and No Adverse Effect Level (NOAEL) were determined from the morphological data as previously described Gustafson et al., 2012) . In the initial AB training set experiments and the first repeat of the test set 5-8 larvae of each concentration group were scored, in the second or third repeat of several compounds in the test set, only 2 concentration groups at or above and below the LC 25 were scored as a means to facilitate identifying the NOAEL and the TI. After scoring, all larvae were euthanized with a 0.25 mg/ ml tricaine solution.
Method for data analysis: teratogenic classification using the TI. Usually developmental in vitro assays use a ratio of a concentration measuring general toxicity (ie, an LC 50 ) and a concentration that measures morphological effects (either an EC50, a LOAEL or NOAEL) to establish a TI Lee et al., 2013; Selderslaghs et al., 2009) . A numerical threshold to classify teratogenicity is typically defined by a training set of known in vivo positive and negative compounds. Brannen et al. (2010) identified an LC 25 /NOAEL (TI) threshold of 10 to discriminate teratogens from nonteratogens. Once the LC 25 and NOAEL were established, the TI or the LC 25 :NOAEL ratio was calculated for each compound. If the TI was !10, then the compound was classified as positive for teratogenic potential, if the TI was <10 then the compound was classified as negative for teratogenicity. All compounds were repeated twice and if the repeat classifications were mismatched (one positive and one negative) then a third experiment was performed and the most frequent classification was used as the final teratogenic classification (frequency analysis).
Analysis for performance evaluation. Performance was determined by Table 1 RESULTS Initial study using AB strain. In this report, 27 compounds were used to calculate the assay concordance instead of the original 31 compounds used in the Brannen et al. study. Because preliminary studies suggested that compounds with H1 histamine and GABA (Gabanergic) activity were misclassified in this assay, the following compounds were not included in the repeat studies: clozapine, Phenobarbital, and valproic acid. BMS-14 was no longer available for repeat studies so it was also not included. Training set data and compound classification is summarized in Supplementary Tables 3a and 3b . AB strain concordance alone is summarized in Table 2 . Based on only the AB strain training set data, the assay's sensitivity was 94% and the specificity was 91%. The concordance for teratogens was 94% (15 out of 16), and for nonteratogens it was 91% (10 out of 11) with a total concordance of 93% (25 out of 27). The false positive and negative error rates were 6 and 9%, respectively ( Table 2) .
Predictivity of the training set including segrest pond fish data. A total of 29 compounds were used to calculate the training set concordance using the repeat wild type Segrest fish data and the frequency analysis. The compounds with H1 histamine and GABA activity compounds listed above, as well as BMS-14 were not repeated with Segrest fish. In addition, 2 compounds with PANZICA-KELLY, ZHANG AND AUGUSTINE-RAUCH | 129 solubility limitations not included in the initial AB strain study were tested at lower concentrations in the repeat studies to make a classification (pergolide mesylate and BMS-9) and were therefore included in the final concordance estimates. Training set data and compound classification incorporating the repeat results is summarized in Supplementary Tables 3a and 3b .
Frequency analysis was applied to calculate the concordance and predictivity and the results are summarized in Table 3 . Based on the entire training set data the assay's sensitivity was 88% and the specificity was 75%. The positive predictivity for teratogens was 83% (15 out of 18), and negative predictivity for nonteratogens was 82% (9 out of 11) with total predictivity of 83% (24 out of 29). The false positive and negative error rates were 17 and 18%, respectively (Table 3) .
Predictivity of the test set. A total of 34 compounds (16 nonteratogens and 18 teratogens) were used in Segrest fish to cross-test the classification model (Supplementary Table 2 ). Test set data and compound classification is summarized in Supplementary  Table 4 . Test set concordance is summarized in Table 4 . Based on the test set data the assay's sensitivity was 78% and the specificity was 69%. The positive predictivity for teratogens was 74% (14 out of 19), and negative predictivity for nonteratogens was 73% (11 out of 15) with total predictivity of 74% (25 out of 34). The false positive and negative error rates were 26 and 27%, respectively (Table 4) . Altogether 63 compounds (28 nonteratogens and 35 teratogens) with known in vivo teratogenicity data were tested to estimate overall performance. The assay's final sensitivity was 83% and the specificity was 71%. The positive predictivity for teratogens was 78% (29 out of 37), and for nonteratogens was 77% (20 out of 26) with total assay predictivity of 78% (49 out of 63). The false positive and negative error rates were 22 and 23%, respectively (Table 5) .
Concordance comparison with different chorion treatment conditions. As a means to determine whether treating and removing the chorion increased sensitivity of the assay, the data generated in this report was compared with chorion-on data generated by a consortium effort (Ball et al., 2014; Gustafson et al., 2012) . A total of 30 compounds were compared (15 teratogens and 15 nonteratogens, Supplementary Table 5 ). In total 14 of 15 nonteratogens and 11 of 15 teratogens were classified correctly with chorion-on embryos, and 12 of 15 nonteratogens and 14 of 15 teratogens were classified correctly with chorion treated/chorion off embryos. Furthermore, as a means to determine whether weakening the chorions by enzymatic treatment classified compounds the same as when the chorions were removed, 19 compounds were repeated with chorion-treated embryos only. The classification between the 2 replicates was the same for all compounds (Supplementary Table 6 ).
Predictivity comparison between full and cut-down score approach. As a means to increase throughput, a comparison between scoring all 4 treatment concentrations and scoring 2 treatment concentration groups (one at or above and one below the LC 25 ) to identify the NOAEL of 25 compounds was performed. The same teratogenic classification was made for every compound using the full or cut-down scoring approaches (Supplementary Table 7 ).
DISCUSSION
Zebrafish have been well demonstrated to be a good model for identifying teratogenic potential of chemicals (Ball et al., 2014; Gustafson et al., 2012; McGrath and Li, 2008; Parng et al., 2002; Selderslaghs et al., 2009; Teixido et al., 2013; Weigt et al., 2011) . However, performance testing with a large test set is the most accurate method for calculating assay predictivity. Previously we described a dechorinated zebrafish teratogenicity assay that achieved 87% concordance with in vivo teratogenicity data. In this report, the initial training set was repeated and an additional test set was used to test assay performance using experimental replicate evaluation throughout the entire compound set. The overall predictivity was 78% with well balanced positive (78%) and negative predictivity (77%) with approximately equal error rates (22-23%) in misclassifying true teratogens and nonteratogens. The teratogenic hit rate (sensitivity) for the training and test set were 88 and 78%, respectively. This difference is likely due to a greater number of potent teratogen in the training compared with the test set. Concordance values derived from other zebrafish developmental screens are very similar to the concordance obtained in this study Truong et al. (2014) that screened >300 EPA compounds (mostly pesticides), the concordance was >60% with approximately 75% teratogenic hit rate (Truong et al., 2014) . The difference in compound class and number confirms that a chorion-off screen combining viability and morphological endpoints regardless of compound type maintains good results.
To establish whether the treatment/removal of the chorion makes a difference in compound classification, a direct comparison between chorion-on and pronase-treated/chorion-off final classification of 30 compounds was made (Supplementary Table 5 ). The chorion-on data was generated during a consortium activity (Ball et al., 2014; Gustafson et al., 2012) . Of the 15 nonteratogens, 14 were classified correctly with chorion-on embryos (93% specificity), and 12 were classified correctly with chorion treated/off embryos (80% specificity). Of the 15 teratogens, 11 were classified correctly with chorion-on embryos (73% sensitivity), and 14 were classified correctly with chorion treated/off embryos (93% sensitivity) (Supplementary Table 5  and Tables 6 and 7) . Although there was a small difference in total concordance (4%), increased sensitivity with pronase treated/chorion-off methods was observed. Other studies have also reported no difference in total concordance between chorion-on vs. chorion-off approaches (Gustafson et al., 2012) and increased sensitivity when using chorion-off embryos (Henn and Braunbeck, 2011; Kim and Tanguay, 2014) . Furthermore, an automated dechorionation system has been developed to increase through-put and to reduce background malformations in manual dechorionation (Mandrell et al., 2012) . Additionally, a recent study that tested 38 compounds with intact chorions determined that 10 of these had low embryo uptake (<5%). When these compounds were retested with higher concentrations up to 1000 mM, the overall assay predictivity improved approximately 5-8%. The final sensitivity ranged from 63 to 74%, and the specificity ranged from 62 to 82% (Ball et al., 2014) . Although chorion treatment/removal versus intact pronasetreated chorions did not affect the total assay performance, permeabilization/removal of the chorion appears to improve sensitivity, achieving 83% sensitivity when compared with the consortium results with intact chorions. Higher sensitivity PANZICA-KELLY, ZHANG AND AUGUSTINE-RAUCH | 131 makes this assay ideal for hazard identification. Additionally, pharmaceutical compound quantities are limited in early discovery; therefore a more sensitive assay requiring less compound is advantageous. Furthermore, uptake analysis, and retesting at higher concentrations requires substantially more compound and is more labor intensive and costly than initially permeabilizing/removing the chorion. Chorion-on screens are still common and there's speculation that information may have been overlooked due to the impermeability of the chorion (Mandrell et al., 2012) . Another important reason for chorion removal is the possibility of compounds that cause hatching inhibition potentially causing secondary morphological effects (Zhou et al., 2009) , hence it is possible that chorion-on assays not only may lead to false negatives, but also false positives. As means to improve assay throughput, several adjustments were made to the procedures. One change consisted of permeabilizing the chorion by enzymatic treatment. Nineteen compounds were first tested with no chorions, and the duplicate experiments were completed with intact, treated chorions. The teratogenic classification with intact chorions was the same for all compounds (Supplementary Table 6 ); therefore another 16 compounds in the test set were analyzed with treated-chorions only. Of these 16, only 2 nonteratogens and 1 teratogen were misclassified (Supplementary Table 5 ). Based on this data, it appears that enzymatic permeabilization of the chorion is a sufficient improvement to increase throughput, thus any additional replicate experiment necessary to complete this study was performed with permeabilized chorions. Another protocol change to increase throughput consisted of scoring only 2 concentration groups below and at or above the LC 25 instead of scoring all 4 concentration groups to identify the NOAEL. Twenty-five compounds (12 teratogens and 13 nonteratogens) were repeated using the cutdown scoring approach. All of these compounds received the same classification when using full or cutdown scoring approaches (Supplementary Table 7 ). Although the cutdown approach considerably increased throughput during scoring, it may fail to provide concentration-response information that may be relevant for other purposes. Overall, there were 8 nonteratogens misclassified in the assay (Supplementary Table 8 ). Three of these were serotonin modulators (fluoxetine, norfenfluramine, pergolide mesylate). Serotonin modulators have been shown to cause locomotive behavior effects in zebrafish larvae (Airhart et al., 2007 (Airhart et al., , 2012 as well as serotonin-related gene expression changes during early zebrafish embryonic development (Airhart et al., 2012; Park et al., 2012) . It is possible that zebrafish are especially sensitive to this compound class. In mammalian embryos, including humans, an ongoing controversy exists regarding whether SSRI serotonin modulations are teratogenic, particularly paroxetine, fluoxetine, and sertraline have been reported in some epidemiology reports to cause increased rates of specific cardiovascular malformations (Louik et al., 2007) . Bisphenol A (BPA) is another nonteratogen incorrectly classified in this model. Evaluation of BPA in zebrafish has shown this compound to alter dorsoventral patterning, segmentation, somatic muscle, and brain segmental pattern formation (Tse et al., 2013) . Furthermore there are controversial reports of effects of BPA in human development and it is considered a suspect human teratogen (Holmes Teratogen report, 2010). BPA has been found to have prenatal epigenetic effects on methylation status of the agouti locus causing enhanced presentation of the agouti obese phenotype in F0 generation mice that were exposed to BPA in utero (Dolinoy et al., 2007) . Thus serotinergic compounds and BPA may be difficult to classify in context of both in vitro and in vivo data.
There were 6 teratogens that were misclassified in this study (Supplementary Table 8 ). Cumulative low incidence of in vivo malformations caused by lithium chloride classifies the compound as a weak teratogen (Gralla and McIlhenny, 1972; Jacobson et al., 1992; Johansen, 1971; Kallen and Tandberg, 1983; Schou and Amdisen, 1971) . In this assay, one experiment classified the compound positive and one negative, therefore a third experiment was completed to make the final classification. This data pattern may be used as a flag for the possibility of weak teratogenic signal and the need to prioritize additional teratogenicity in vitro screens to confirm assessment. Another misclassified teratogen was the COX2 inhibitor, BMS-9. This compound was insoluble at concentrations >10 mM, and an LC 25 could not be achieved due to these solubility limitations. This compound was removed from the training set in the initial study due to insufficient solubility, but it was added back into this assessment to demonstrate the issues that may be encountered with this assay. In the replicate experiments, sufficient solubility was achieved to make a classification. This compound was tested in other teratogenicity in vitro assays using a Data obtained from an inter-laboratory assessment (Ball et al., 2014; Gustafson et al., 2012) .
tiered screening strategy and was ultimately correctly classified as teratogenic. Although the total concordance of the zebrafish teratogenicity assay is considered relatively good, it may have enhance predictivity when the assay is used in combination with other in vitro assays to make a final classification. Specific compound classes may be more/less sensitive in some species over others leading to the misclassification of a compound. For example, incorrectly classified teratogens were ultimately correctly classified (5-fluorouracil, ribaviron, hydroxyurea) utilizing data from different in vitro screens, this may be due to species differences in teratogenic sensitivity or related to embryo uptake issues associated with the zebrafish model (Ball et al., 2014) .
In our hands, a multi-assay screening approach is used for teratogenic classification of uncharacterized compounds, where the zebrafish embryo culture assay is currently used in combination with rat whole embryo culture and the molecular embryonic stem cell assay (Panzica-Kelly et al., 2013) in a tiered or frequency approach to make a final teratogenic classification. Of 31 teratogens tested in all 3 screens, 4 of these were misclassified by the zebrafish assay, but 3 of 4 were classified correctly when all 3 assays were used to make a final classification. Applying tiered or frequency approaches from multiple assay data considerably enhances overall predictivity to 88-89% (Augustine-Rauch et al., submitted).
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